Table 2 Correlation analysis between CD27 expression level and short-term efficacy
From: Prognostic marker CD27 and its micro-environmental in multiple myeloma
Characteristic | CD27 + group (n = 60) | CD27-group (n = 22) | P value |
|---|---|---|---|
Immunomodulatory -based regime (VRD) | 22(36.67%) | 12(54.55%) | 0.145 |
Chemotherapy-based regime (PCD/PAD) | 38(63.33%) | 10(45.45%) | 0.145 |
sCR | 0(0.00%) | 1(4.55%) | 0.097 |
CR | 4(6.67%) | 5(22.73%) | 0.039 |
VGPR | 10(16.67%) | 6(27.27%) | 0.283 |
PR | 19(31.67%) | 6(27.27%) | 0.702 |
SD | 16(26.67%) | 2(9.09%) | 0.088 |
PD | 11(18.33%) | 2(9.09%) | 0.310 |
ORR | 33(55.00%) | 18(81.82%) | 0.026 |
sCR + CR + VGPR | 14(23.33%) | 12(54.55%) | 0.007 |
SD + PD | 27(45.00%) | 4(18.18%) | 0.026 |